FORMULATION AND DEVELOPMENT OF HYDROCHLOROTHIAZIDE FLOATING MICROSPHERES
About Authors:
RAVIKUMAR R. PATEL1, Dr. JAYVADAN K. PATEL2
1 Research Scholar, Jodhpur National University, Jodhpur
2 Principal and Professor, Nootan Pharmacy College, Visnagar, Mehsana, Gujarat.
AIM OF PRESENT INVESTIGATION
Now a day most of the pharmaceutical scientists are involved in developing an ideal drug delivery system with an objective of not only curing the disease but also to achieve patient compliance. Approximately 50 % of the drug delivery system available in market is oral drug delivery system. Conventional oral dosage forms provide a specific drug concentration in systemic circulation without offering any control over drug delivery. Over the past three decades, the pursuit and exploration of devices designed to be retained in the upper part of gastrointestinal tract has advanced consistently in terms of technology and diversity, encompassing a variety of systems and devices such as floating systems.

Glenmark Pharmaceuticals today announced the settlement of litigation with Daiichi Sankyo and Genzyme Corporation regarding Glenmark's Abbreviated New Drug Application (ANDA) tiled with the US Food and Drug Administration (FDA) for Colesevelam Hydrochloride, a drug used in treatment of type-2 diabetes.
Cadila Pharmaceuticals Ltd. (CPL) Is one of India’s most reputed, research-based, techno-savvy pharmaceutical companies with a focus in the area of Formulations & APIs and having its Corporate Office at Bhat, Ahmedabad and State-of-art manufacturing facilities at Dholka, Ankleshwar, Kadi and Jammu accredited with USFDA, MHRA, TGA, MCA, MCC & WHO certifications.

